- Home
- LZMH vs LGND Comparison
LZMH vs LGND Comparison
Compare LZMH & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZMH
- LGND
- Stock Information
- Founded
- LZMH 2014
- LGND 1987
- Country
- LZMH China
- LGND United States
- Employees
- LZMH N/A
- LGND N/A
- Industry
- LZMH
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- LZMH
- LGND Health Care
- Exchange
- LZMH NYSE
- LGND Nasdaq
- Market Cap
- LZMH 2.0B
- LGND 2.0B
- IPO Year
- LZMH 2025
- LGND 1992
- Fundamental
- Price
- LZMH $24.77
- LGND $101.64
- Analyst Decision
- LZMH
- LGND Strong Buy
- Analyst Count
- LZMH 0
- LGND 8
- Target Price
- LZMH N/A
- LGND $144.71
- AVG Volume (30 Days)
- LZMH 434.6K
- LGND 118.0K
- Earning Date
- LZMH 01-01-0001
- LGND 05-08-2025
- Dividend Yield
- LZMH N/A
- LGND N/A
- EPS Growth
- LZMH N/A
- LGND N/A
- EPS
- LZMH N/A
- LGND N/A
- Revenue
- LZMH $113,861,206.00
- LGND $181,488,000.00
- Revenue This Year
- LZMH N/A
- LGND $17.68
- Revenue Next Year
- LZMH N/A
- LGND $18.69
- P/E Ratio
- LZMH N/A
- LGND N/A
- Revenue Growth
- LZMH 166.00
- LGND 53.40
- 52 Week Low
- LZMH $4.40
- LGND $77.43
- 52 Week High
- LZMH $32.10
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- LZMH N/A
- LGND 43.29
- Support Level
- LZMH N/A
- LGND $98.89
- Resistance Level
- LZMH N/A
- LGND $104.01
- Average True Range (ATR)
- LZMH 0.00
- LGND 2.97
- MACD
- LZMH 0.00
- LGND -0.20
- Stochastic Oscillator
- LZMH 0.00
- LGND 28.77
About LZMH LZ TECHNOLOGY HOLDINGS LIMITED
LZ Technology Holdings Ltd conducts its operations through operating entities formed in the PRC, Lianzhang Portal and its subsidiaries. The Company is an information technology and advertising company with operations organized into three business verticals: (i) Smart Community, (ii) Out-of-Home Advertising, and (iii) Local Life.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.